Failed Cancer Drug Trial Drives GPC Biotech (GPCB) Down 62%
Shares of GPC Biotech (GPCB) are off 62% before the open. GPCB announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate cancer did not ...Read Full Story »

